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Rationale: Combination therapy with corticosteroid and long-acting b2-agonists (LABA) in
a single inhaler is associated with superior effects on airway function and exercise perfor-
mance in COPD compared with LABA monotherapy. The physiological effects of adding inhaled
corticosteroid monotherapy to maintenance bronchodilator therapy (long-acting anticholiner-
gics and LABA singly or in combination) in COPD are unknown.
Methods: This was a randomized, double-blind, placebo-controlled, crossover study
(NCT00387036) to compare the effects of inhaled fluticasone propionate 500 mg (FP500)
twice-daily and placebo (PLA) on airway function during rest and exercise, measured during
constant work rate cycle exercise at 75% of maximum incremental cycle work rate, in 17
patients with COPD (FEV1  70% predicted).
Results: After treatment with FP500 compared to PLA, there were significant increases in post-
dosemeasurementsofFEV1 (þ115mL,PZ0.006)andtheFEV1/FVCratio (þ2.5%,PZ0.017),along
with decreases in plethysmographic residual volume (0.32L; PZ 0.031), functional residual
capacity (0.30L, PZ 0.033), and total lung capacity (0.30L, PZ 0.027) but no changes in vital
capacity or inspiratory capacity (IC). Post-treatment comparisons demonstrated a significant
improvement in endurance time by 188  362 s with FP500 (PZ 0.047) with no concomitant
increase in dyspnea intensity. End-inspiratory and end-expiratory lung volumes were reduced at
rest and throughout exercise with FP500 compared with PLA (P < 0.05).
Conclusion: Inhaled FP500 monotherapy was associated with consistent and clinically important
improvements in FEV1, static lung volumes, dynamic operating lung volumes, and exercise endur-
ance when added to establishedmaintenance long-acting bronchodilator therapy in patients with
moderate to severe COPD.
ª 2011 Elsevier Ltd. All rights reserved.espiratory and Critical Care Medicine, Queen’s University , 102 Stuart Street, Kingston, ON, Canada
þ1 613 548 1307.
.ca (D.E. O’Donnell).
1 Elsevier Ltd. All rights reserved.
Inhaled corticosteroids and exercise responses in COPD 1837Introduction
dation treatment with long-acting anticholinergic or b2-Treatment with an inhaled corticosteroid (ICS) is indicated
for the prevention of exacerbations in patients with
moderate to severe chronic obstructive pulmonary disease
(COPD) who are prone to exacerbations.1,2 ICS mono-
therapy is associated with modest improvements in trough
FEV1 but their long term use has not been shown to delay
the rate of decline of FEV1 over time.
3e5 In contrast to the
effects of bronchodilators in COPD, improvement in airway
function with ICS monotherapy is more gradual and of lesser
magnitude. The underlying mechanisms are unknown but
are postulated to be linked to reduced airway mucosal
inflammation and edema.6,7
A number of studies have shown that when ICS and long-
acting b2-agonists (LABA) are delivered as fixed combina-
tion in a single inhaler, their effect on airway function and
respiratory symptoms is superior to the LABA component
alone.8e10 Worth et al.11 recently reported that one week
treatment with combined budesonide/formoterol (320/
9 mg b.i.d.) therapy was associated with greater cycle
exercise endurance time (by 69 s) compared with for-
moterol alone in patients with moderate to severe COPD.
Similar improvement trends were seen in a study by our
group which conducted a secondary analysis on the
comparative effects of fluticasone/salmeterol (250/
50 mg b.i.d.) and salmeterol alone on pulmonary function
and exercise endurance.12 That study was primarily
designed to examine physiological differences between
fluticasone/salmeterol combination and placebo and was
not sufficiently powered to compare the effects of the
combination vs. salmeterol. However, it is evident from
these two studies that when ICS is added to LABA in a single
combination inhaler, bronchodilation and lung deflation is
amplified and exercise tolerance is improved as early as 2 h
after dosing.
It is not known if the additive effects of ICS are
restricted to the ICS/LABA combination or whether similar
improvements are seen when ICS is added to other bron-
chodilator classes such as inhaled long-acting anticholin-
ergics. Moreover, the mechanisms of improved airway
function when ICS is added to a bronchodilator are also
unknown. Potential but unproven mechanisms of improved
airway function proposed in asthma are: 1) the non-
genomic effects of corticosteroids on the airway vascula-
ture and 2) inhibitory effects on airway smooth muscle
contraction.13,14 In the study of Worth et al.,11 differences
in reduction of resting lung hyperinflation between the
combination treatment and the LABA alone were not
significant and the small improvements in dynamic inspi-
ratory capacity recorded during exercise seem unlikely to
account for all of the increased exercise tolerance. The
question arises whether other physiological effects of ICS
previously described in asthma (but not in COPD) during
exercise, such as improved arterial oxygenation,15
contribute to improved exercise tolerance. The present
study is the first to evaluate the effects of an ICS on airway
physiology during rest and exercise in patients established
on a maintenance long-acting bronchodilator regimen.
The main purpose of the current study was therefore to
increase our understanding of the short term physiologicaleffects of ICS monotherapy when added to regular foun-
agonists bronchodilators (singly or in combination). We
wished to determine if added ICS therapy was associated
with additional improvement in dyspnea intensity during
standardized exercise tests and to identify potential
underlying mechanisms. We hypothesized that adjunct
short term treatment with inhaled fluticasone propionate
would be associated with a reduction in exertional dyspnea
ratings and that this in turn would be related to improve-
ments in dynamic respiratory mechanics. We therefore
conducted a crossover study in 17 patients with moderate
to severe COPD who were randomized to FP500 or placebo
(PLA) for a 2 week period. We undertook within-subject
comparisons of dyspnea intensity ratings at a standardize
endurance time (primary outcome), resting pulmonary
function tests, exercise endurance, breathing pattern,
operating lung volumes, cardio-metabolic and pulmonary
gas exchange parameters after treatment with active drug
or PLA.
Methods
Subjects
Subjects included clinically stable COPD patients 40 years
of age with a clinical diagnosis of COPD for at least 1 year,
a cigarette smoking exposure 20 pack-years, an
FEV1  70% predicted, an FEV1/FVC  0.7, FRC  120% of
predicted and moderate to severe chronic activity-related
dyspnea as evidenced by a modified Baseline Dypspnea
Index focal score 6.16 Patients were excluded if they had
a history of asthma or any condition other than COPD that
might contribute to dyspnea or exercise intolerance, if they
were hospitalized or had signs of a lower respiratory tract
infection 4 weeks prior to the first experimental visit, or if
they had an oxygen saturation 80% during exercise on
room air.
Study design
This double-blind, placebo-controlled crossover comparison
study (ClinicalTrials.gov registration number: NCT00387
036) received ethical approval from the University and
Hospital Human Research Ethics Board (ID#: DMED-949-06)
and all subjects gave informed written consent prior to
participating. On visit 1, subjects underwent screening
procedures to determine eligibility including complete
pulmonary function testing and an incremental cardiopul-
monary exercise test on a cycle ergometer to determine
peak exercise work rate. On visit 2, subjects performed
pulmonary function tests and a constant-load cycling test at
75% of peak work rate (as determined from visit 1) for
familiarization purposes. Patients meeting all eligibility
requirements entered the active treatment period of the
study where they received, in a double-blind manner,
inhaled fluticasone propionate 500 mg (FP500) or matching
PLA added twice-daily to their normal daily drug regimen
for 2 weeks. At the beginning of each treatment period
(visits 3 and 5), subjects performed baseline pulmonary
function tests followed by a constant-load exercise test
1838 J.A. Guenette et al.(pre-treatment). At the end of each treatment period (visit
4 and 6), subjects performed pulmonary function tests
before (post-treatment, pre-dose) and 2 h after receiving
study treatment (post-treatment, post-dose), followed by
a constant-load exercise test (post-treatment, post-dose).
Between treatment periods, all subjects underwent
a single-blind placebo washout phase for 2 weeks. Patients
were required to refrain from using all systemic steroids
(for at least 2 months) or inhaled corticosteroids (for at
least 2 weeks) prior to visit 1 until the study was
completed. All subjects maintained their use of short- and
long-acting bronchodilators throughout the duration of the
study. Prior to each visit, short-acting bronchodilators and
short- and long-acting theophyllines were withdrawn for at
least 6, 24, and 48 h, respectively. Patients also withheld
the study medication on the morning of all visits to facili-
tate the timing of post-dose procedures following wit-
nessed in-clinic dosing. Subjects avoided caffeine, heavy
meals, alcohol and strenuous exercise prior to each visit.
The primary endpoint of this study was the modified
Borg dyspnea score measured at a standardized time during
constant-load exercise. Secondary endpoints included cycle
endurance performance, spirometric parameters, and
static and dynamic lung volumes.
Pulmonary function
Spirometry, constant-volume body plethysmography,
single-breath diffusing capacity for carbon monoxide and
maximal mouth pressures were performed according to
recommendations17e21 using an automated testing system
(Vs62j Body Plethysmograph and Vmax229d; SensorMedics,
Yorba Linda, CA). All measurements are expressed as
percentages of predicted normal values.22e27 Predicted
inspiratory capacity was determined as the difference
between predicted total lung capacity and predicted
functional residual capacity.
Cardiopulmonary exercise testing
Symptom-limited exercise tests were performed on an
electronically braked cycle ergometer (Ergometrics 800S;
SensorMedics) using the Vmax229d Cardiopulmonary Exer-
cise Testing System (SensorMedics) according to recom-
mended guidelines28 and as previously described.29 The
incremental exercise test on visit 1 consisted of steady-
state rest, a 1 min warm-up, and 10 W stepwise increases
in work rate every 1 min until symptom-limitation (i.e.,
peak exercise). Maximal work rate was defined as the
highest work rate that could be sustained for 30 s.
Constant-load exercise tests involved a period of steady-
state rest, a 1 min warm-up and an immediate increase in
work rate corresponding to 75% of maximal work (as
determined on visit 1) until symptom limitation. Constant-
load endurance time was defined as the duration of
loaded pedaling.
Measurements
Subjects rated the intensity of their “breathing discomfort”
and “leg discomfort” at rest and throughout exercise bypointing to a modified 10-point Borg scale. The scale’s
endpoints were anchored such that ‘0’ represented “no
breathing/leg discomfort” and ‘10’ represented “the most
severe breathing/leg discomfort ever experienced or
imagined.” At exercise cessation, subjects verbalized their
main reason for stopping exercise. Arterial oxygen satura-
tion by pulse oximetry, heart rate by electrocardiography,
and blood pressure by auscultation were measured at rest
and throughout exercise. Minute ventilation (V’E), oxygen
consumption (V’O2), carbon dioxide production (V’CO2),
partial pressure of end-tidal CO2 (PETCO2), tidal volume
(VT), and breathing frequency were measured breath-by-
breath and averaged over 30 s epochs. Changes in oper-
ating lung volumes were derived from dynamic inspiratory
capacity measurements.30 Assuming that TLC remains
constant throughout exercise,31 changes in IC reflect
changes in end-expiratory lung volume (EELV Z TLC  IC),
and changes in inspiratory reserve volume (IRV Z IC  VT)
reflect changes in end-inspiratory lung volume
(EILV Z TLC  IRV). IC maneuvers were performed during
the final 30 s of each 2 min exercise period. All breath-by-
breath ventilatory and metabolic data were analyzed over
the first 30 s period of each second minute during exercise
and was linked with symptom ratings and IC measurements
obtained during the final 30 s of each second minute. This
was done to avoid contamination of averaged breath-by-
breath data surrounding an IC maneuver.
Statistical analysis
The sample size of 17 provides the power (80%) to detect
a significant difference in dyspnea intensity measured at
a standardized time during exercise based on a 1 Borg unit
difference, a standard deviation based on values estab-
lished in our laboratory from a similar group of COPD
patients (n Z 105), and a two-tailed test of significance.
Primary analysis was performed on post-dose measure-
ments. Possible carry-over and period effects were
assessed according to recommended guidelines for cross-
over trials.32 Treatment responses were compared using
paired t-tests. Exercise responses were compared at iso-
time (i.e., the highest equivalent time achieved in all
constant-load exercise tests) and at peak exercise and also
as slopes derived from linear regression analysis of data
sets from each individual during exercise. Reasons for
stopping exercise and descriptors of breathlessness were
analyzed using Fisher’s exact test. Pearson’s correlation
was performed using the difference in endurance time
(FP500 vs. PLA) at isotime as the dependent variable and
differences in selected measurements as independent
variables. A P < 0.05 significance level was used for all
analysis. Results are reported as mean  SD unless other-
wise specified.
Results
Seventeen subjects with moderate to severe COPD and
significant chronic activity-related dyspnea completed this
study and are described in Table 1. Exercise capacity
during the incremental exercise test was reduced primarily
due to severe dyspnea; i.e., 76% stopped exercise due to
Inhaled corticosteroids and exercise responses in COPD 1839breathing discomfort (nZ 7) or a combination of breathing
and leg discomfort (n Z 6). Treatment order was balanced
such that 8 subjects (47%) were randomized to FP500 first.
All subjects were on baseline inhaled long-acting bron-
chodilators. At the time of testing, 13/17 (76%) were on
both a long-acting anticholinergic and a long-acting b2-
agonist, 2/17 (12%) were on a long-acting anticholinergic
medication alone and 2/17 (12%) were on a long-acting b2-
agonist alone. Four of the 17 patients were naive to ICS
therapy. All patients that were not naive stopped their ICS
treatment at least 2 weeks prior to the first visit. All
patients had a short-acting bronchodilator to use as needed
and 2/17 (12%) also had a short-acting inhaled anticholin-
ergic to use as needed.Table 1 Subject Characteristics.
Measurement Value
Males:females (n) 12:5
Age (years) 67.2  6.9
Height (cm) 171  7
Mass (kg) 76  11
BMI (kg/m2) 26.0  3.0
Smoking history (pack-years) 54  31
Duration of COPD (years) 6.6  6.9
BDI (focal score) 5.1  1.1
FEV1 (L) 1.45  0.51
FEV1 (% predicted) 54  11
FEV1/FVC (%) 40  6
FVC (L) 3.66  1.20
FVC (% predicted) 94  18
IC (L) 2.71  0.90
IC (% predicted) 92  19
TLC (L) 7.51  1.17
TLC (% predicted) 120  11
FRC (L) 4.80  0.84
FRC (% predicted) 144  25
RV (L) 3.58  0.88
RV (% predicted) 158  38
sRaw (cm H2O s) 21.0  9.3
sRaw (% predicted) 487  203
DLCO/VA (mL/min/mmHg/L) 2.24  0.73
DLCO/VA (% predicted) 60  19
Medications:
Salbutamol n Z 17
Ipratropium n Z 2
Salmeterol n Z 9
Formoterol n Z 4
Tiotropium n Z 15
Fluticasone n Z 1
Salmeterol/Fluticasone n Z 10
Budesonide/Formoterol n Z 3
Data are presented as mean  SD. BMI, body mass index; BDI,
modified baseline dyspnea index; FEV1, forced expiratory
volume in 1 s; FVC, forced vital capacity; IC, inspiratory
capacity; TLC, total lung capacity; FRC, functional residual
capacity; RV, residual volume; sRaw; specific airways resis-
tance; DLCO, single-breath diffusing capacity of the lung for
carbon monoxide; VA, alveolar volume.
* Inhaled corticosteroids withdrawn  2 weeks prior to study.Pulmonary function
Post-dose comparisons demonstrated that FP500 resulted in
a significant increase in FEV1 and FEV1/FVC and a reduction
in TLC, FRC and RV following 2 weeks of treatment relative
to PLA (Table 2). There were no pre-dose vs. 2 h post-dose
differences in pulmonary function parameters following
treatment for both PLA and FP500.
Exercise endurance
Endurance time during the constant-load cycling test was
not different between pre- and post-treatment PLA
(604  430 vs. 583  381 s, respectively, P > 0.05). Post-
treatment comparisons of constant-load cycling demon-
strated a significant improvement in endurance time by
188  362 s (P Z 0.047) following FP500 compared with
PLA (Table 3). Fig. 1 shows the change in endurance time
in individual subjects. The majority of subjects (n Z 13)
increased their endurance time (range: 28e890 s) with 11
reaching the minimal clinically important difference of
w100 s.33 Four subjects had variable reductions in
endurance time (range: 8e635 s). Two subjects had
unusual increases in endurance time by 890 and 819 s and
one had a significant reduction in endurance time by
635 s. Removal of these three outliers reduced the
observed mean improvement in performance from 188 s to
152 s but improved statistical significance from
a P Z 0.047 to P Z 0.013. Improvements in endurance
time were not related to improvements in resting
pulmonary function.
Sensory responses
Ten patients had a 1 Borg unit reduction in dyspnea at
isotime (range 1e4 Borg units), 3 patients had no change in
dyspnea rating, and 4 patients had a 1 Borg unit increase
in dyspnea ratings (range 1e2.5 Borg units). As a group,
there were no statistically significant changes in breathing
or leg discomfort during exercise (Fig. 2) but FP500 allowed
subjects to tolerate similar levels of dyspnea for a longer
duration. Dyspnea/V’E slopes were not different following
treatment between PLA and FP500 (0.42  0.44 vs.
0.34  0.22, respectively, P > 0.05). There was a modest
correlation between change in dyspnea isotime rating and
change in endurance performance between PLA and FP500
(r Z 0.44) but this was not statistically significant
(P Z 0.07). Primary reasons for stopping exercise with PLA
[breathing (n Z 8); legs (n Z 4); combination (n Z 5);
other (n Z 0)] were not significantly different from FP500
[breathing (n Z 5); legs (n Z 5); combination (n Z 6);
other (n Z 1)].
Physiological responses during exercise
Ventilatory and physiological data at isotime and peak
exercise following treatment are shown in Table 3. There
was a trend for breathing frequency to decrease (Fig. 3,
P Z 0.06) and DIC (from rest) to decrease (Table 3,
P Z 0.08) at isotime following FP500 treatment. Operating
lung volumes (i.e., EELV and EILV) were consistently
Table 2 Post-treatment and post dose pulmonary function tests.
Measurement Placebo Fluticasone
FEV1 (L) 1.50  0.56 1.61  0.58*
FEV1/FVC (%) 39  6 42  5*
FVC (L) 3.78  1.24 3.84  1.22
PEF (L/sec) 5.14  1.47 5.24  1.46
FEF25e75 (L/sec) 0.43  0.19 0.46  0.17
IC (L) 2.71  0.95 2.71  0.92
TLC (L) 7.46  1.46 7.16  1.38*
FRC (L) 4.76  0.89 4.45  0.93*
RV (L) 3.42  0.88 3.10  0.86*
sRaw (cm H2O s) 19.8  8.0 18.5  8.4
Data are presented as mean  SD. FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow; FEF25e75,
mean forced expiratory flow between 25% and 75% of FVC; IC, inspiratory capacity; TLC, total lung capacity; FRC, functional residual
capacity; RV, residual volume; sRaw; specific airways resistance. There were no pre- to post-dose differences for either placebo or
fluticasone. *P < 0.05, post-dose placebo vs. post-dose fluticasone.
1840 J.A. Guenette et al.reduced at rest and throughout exercise when expressed as
a percentage of predicted TLC (Fig. 4) or when expressed in
absolute terms (Table 3). At peak exercise, there was
a trend for a higher heart rate (P Z 0.06) following FP500
(Fig. 5 and Table 3) with no significant differences in oxygen
saturation (Fig. 5).Table 3 Post-dose cardioerespiratory and perceptual respons
treatment period.
Measurement Isotime
Placebo Flut
Time (min) 444  390 444
Dyspnea (Borg) 4.6  2.6 3.9
Leg Discomfort (Borg) 5.3  2.9 4.8
HR (beats/min) 118  17 117
O2 pulse (ml/beat) 10.5  3.5 10.3
V’O2 (L/min) 1.24  0.47 1.21
V’CO2 (L/min) 1.25  0.48 1.23
V’E (L/min) 43.9  14.6 43.0
V’E/V’CO2 36.4  1.4 36.2
fR (breaths/min) 29.5  4.5 27.9
VT (L) 1.49  0.43 1.53
TI (sec) 0.82  0.18 0.88
TE (sec) 1.28  0.28 1.32
TI/TTOT (%) 38.9  4.3 39.7
IC (L) 2.21  0.67 2.26
DIC from rest (L) 0.51  0.40 0.42
IRV (L) 0.69  0.42 0.73
EELV (L) 5.33  1.08 4.90
EILV (L) 6.85  1.32 6.44
PETCO2 (mmHg) 34.8  3.8 35.8
SpO2 (%) 92.9  3.8 93.0
Data are presented as mean  SD. HR, heart rate, V’O2, oxygen upta
ratio; V’E, minute ventilation; fR, breathing frequency; VT, tidal volum
TTOT, inspiratory duty cycle; IC, inspiratory capacity; DIC, change in
hyperinflation); IRV, inspiratory reserve volume; EELV, end-expiratory
pressure of end-tidal CO2; oxyhemoglobin saturation measured by pu
a P < 0.05, post-dose placebo vs. post-dose fluticasone.
b P  0.08, post-dose placebo vs. post-dose fluticasone.Discussion
The novel finding of this study was that the addition of
FP500 to regular long-acting bronchodilator therapy was
not associated with an improvement in standardized dysp-
nea ratings during exercise but was associated withes during constant-load exercise at the end of each 2-week
Peak
icasone Placebo Fluticasone
 390 583  381 771  596a
 2.1 5.9  2.2 6.5  2.7
 2.1 6.5  2.6 7.2  2.5
 18 120  16 124  17b
 3.2 10.7  3.3 10.4  3.2
 0.43 1.28  0.43 1.29  0.43
 0.45 1.29  0.43 1.30  0.43
 13.9 45.4  12.9 46.0  13.1
 1.5 36.2  1.3 36.4  1.5
 4.1b 31.1  4.2 30.6  4.0
 0.41 1.47  0.42 1.51  0.41
 0.17b 0.76  0.13 0.77  0.13
 0.23 1.23  0.20 1.23  0.24
 4.9 38.5  4.2 38.8  4.1
 0.66 2.18  0.69 2.14  0.64
 0.31b 0.54  0.41 0.54  0.38
 0.41 0.68  0.41 0.63  0.37
 1.04a 5.36  1.09 5.02  1.06a
 1.21a 6.86  1.28 6.53  1.23a
 4.8 34.8  3.7 35.3  4.5
 3.7 91.9  4.3 92.5  3.6
ke; V’CO2, carbon dioxide production; RER, respiratory exchange
e; TI, inspiratory time; TE, expiratory time; TTOT, total time, TI/
inspiratory capacity from rest (i.e., magnitude of dynamic lung
lung volume; EILV, end-inspiratory lung volume; PETCO2, partial
lse oximetry.
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Figure 1 Change in constant-load endurance performance in all subjects (i.e., the difference between post-treatment placebo
and post-treatment fluticasone). Horizontal dashed line represents the minimum clinically important difference (MCID) of
w100 s.33
Inhaled corticosteroids and exercise responses in COPD 1841significant improvements in spirometry, lung hyperinflation
and exercise tolerance when compared with PLA in stable
patients with moderate to severe COPD.
Study patients experienced moderate to severe activity-
related dyspnea despite regular foundation treatment with
long-acting bronchodilators. Peak oxygen uptake and work
rate were reduced by 31 and 47% of predicted normal values,
respectively, mainly as a result of critical ventilatory
constraints and attendant dyspnea. During the course of the
study, all patients continued their usual bronchodilators as
prescribed by their physician: the majority (76%) received
both a long-acting anticholinergic and b2-agonist; the
remainder received a long-acting anticholinergic alone (12%)
or a long-acting b2-agonist alone (12%).
Adjunct treatment with FP500 over a 2 week period was
associated with consistent reductions in all lung volume
components: RV, FRC, and TLC were reduced by approxi-
mately 0.3 L. Unlike previous studies that examined bron-
chodilator efficacy in patients of similar COPD severity,
reductions in RV and FRC following ICS were not associated
with significant reciprocal increases in VC and IC, respec-
tively.34,35 Thus, there was a net reduction in TLC and the
FEV1/FVC ratio improved. This contrasts with the results of
studies of single long-acting bronchodilators where the
FEV1/FVC ratio is unchanged.
35,36 The improvement in FEV1
(by 115 ml) after FP500 compared with PLA is surprisingly
large, particularly since this occurred in the setting of
baseline dual long-acting bronchodilators in the majority.
We were not able to determine the differential effects of
adjunct ICS on small and large airway function or theVE (L
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Figure 2 Post-treatment and post-dose sensory responses to co
presented as mean  SE.precise biologic mechanisms of improvement in this study.
However, the consistent reduction in lung volume compo-
nents with ICS vs. PLA points to improvements in airway
conductance and in the mechanical time constant for
emptying of heterogeneously distributed alveolar units.
When ICS is given as sole therapy (without bronchodila-
tors) small improvements in airway function have been
reported compared with PLA after 2 weeks of treatment.37
In a systematic review of several clinical trials, Sin et al.38
noted an average increase in baseline trough FEV1 of only
45 ml in the first 6 months of ICS monotherapy. Another
meta-analysis of 12 placebo-controlled trials demonstrated
that ICS induced a mean increase in FEV1 by 96 ml after 1e6
months and 51 ml after 1e3 years.39 Specific clinical trials
such as the ISOLDE trial3 showed that FEV1 with ICS was
higher than placebo by at least 70 ml at each time point
throughout the 36 month trial. In the TRISTAN8 and TORCH40
trials, ICS monotherapy increased post-bronchodilator FEV1
by approximately 45 ml compared with placebo. In the
present study where patients received baseline broncho-
dilator therapy, larger effects were seen after only 2 weeks
of ICS treatment. The improvements in airflow rates and
lung hyperinflation could represent an additive or syner-
gistic bronchodilation effect which has been reported when
ICS and long-acting b2-agonist treatment are combined in
a single device.8e10 A number of theoretical mechanisms
could explain this. For example, ICS may enhance the
bronchodilation of LABA by DNA transcription thus
increasing adrenergic receptor gene expression. Alterna-
tively, or in addition, ICS may act acutely by direct/min)
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Figure 3 Post-treatment and post-dose ventilatory and breathing pattern response to constant-load cycle exercise. V’E, minute
ventilation; VT, tidal volume; fR, breathing frequency. Data are presented as mean  SE. yP Z 0.06.
1842 J.A. Guenette et al.inhibition of extraneuronal catecholamine transporter
which may result in enhanced availability and action of
norepinephrine with consequent greater bronchodilation.41
Other non-genomic actions of ICS which have been shown in
asthma are enhancement of norepinephrine-induced bron-
chial vasoconstriction which may act to reduce mucosal
edema.6,7 Thus, it is conceivable that ICS may enhance the
action of bronchodilators by reducing their clearance from
the airways.42 However, one previous study found no
evidence of either increased bronchial blood flow or vaso-
constriction with inhaled budesonide in COPD.43
The primary outcome was not met: FP500 treatment was
not associated with improved submaximal dyspnea ratings.
However, adjunct ICS was associated with a significant
improvement in exercise endurance time by an average of
188 s which exceeds current estimates of the minimal
clinically important difference for constant-load cycle tests
at 75% of maximum work rate (i.e., w100 s).33 The high
intensity constant work rate protocol used here has been
shown to be reproducible and responsive in the multi-
center trial setting.44 However, in this study the change
in endurance time across patients in association with FP500
tended to be more variable (Fig. 1). This large variability in
endurance performance was unexpected and difficult to
explain but may be related to both methodological and
physiological factors. For example, it is possible that theFigure 4 Post-treatment and post-dose operating lung
volumes vs. minute ventilation during constant-load cycle
exercise. TLCpred, predicted total lung capacity; EELV, end-
expiratory lung volume; EILV, end-inspiratory lung volume; V’E,
minute ventilation. Data are presented as mean  SE.
*P < 0.05.peak incremental work rate was underestimated in some
subjects resulting in longer than average constant-load
durations at work rates below the individual’s critical
power, which may have contributed to an increase in
baseline endurance variability. The variability may also
have been attributable to individual responses to FP500 due
to potential differences in airway inflammation (eosini-
philic vs. neutrophilic) although this was not specifically
assessed in the present study and every effort was made to
exclude asthmatic patients. The lack of correlation
between improved endurance time and pulmonary function
makes this latter possibility less likely. Despite the vari-
ability in endurance performance, the majority (13/17)
showed improvement with 11 reaching a clinically mean-
ingful increase (Fig. 1). Removal of three outliers (with an
unusually large decrease or increase in exercise perfor-
mance) reduced the mean improvement to 152 s but
increased the overall level of statistical significance. This
improvement is broadly comparable to that reported in two
previous studies that compared combination ICS/LABA in
a single inhaler to PLA.11,12
Improvement in exercise tolerance following bronchodi-
lator treatment alone or in combination with ICS has been
linked to improvements in resting and exercise IC with
consequent greater VT expansion and a delay in reaching
critical mechanical constraints and the attendant intolerable
dyspnea.12,34,35 By contrast, in this study there was no
significant improvement in resting IC, breathing pattern or
ventilation with the addition of FP500, and submaximal
dyspnea intensity ratings were not significantly reduced at
a given time or ventilation. Moreover, improvements in
pulmonary function were not correlated with increases in
endurance time.With FP500 treatment, patientswere able to
meet the increased ventilatory requirements of exercise by
breathingat a lower absolute lungvolume thanwithPLA:EELV
was diminished at rest and throughout exercise by an average
of w0.35 L. It is possible therefore that an improvement in
operating length of the respiratory muscles (particularly the
diaphragm) together with improved airway conductance,
contributed to the ability of our patients to exercise for
a longer duration without a significant increase in dyspnea. It
is also possible, but unproven, that topical FP500 (via genomic
or non-genomic mechanisms) can modulate respiratory
sensation, independent of changes in airway function, by
altering afferent activity from sensory receptors in the airway
mucosa, as has been postulated in asthma.45,46
Havercamp et al.15 have described consistent improve-
ments in arterial oxygenation in asthmatics following ICS
Figure 5 Post-treatment and post-dose heart rate and arterial oxygen saturation response to constant-load cycle exercise. SpO2,
pulse oximetry derived arterial oxygen saturation. Data are presented as mean  SE. yP Z 0.06.
Inhaled corticosteroids and exercise responses in COPD 1843monotherapy which contributed to improvements in exer-
cise performance. In the current study, this mechanism is
unlikely to be important as indices of pulmonary gas
exchange were comparable during FP500 and PLA. Inter-
estingly, arterial O2 desaturation was not significantly
increased during FP500 treatment despite the longer
exercise duration, suggesting possible minor improvements
in ventilationeperfusion relations at higher ventilations.Limitations
This study was an exploratory physiological study with
a relatively small sample size. The study was powered to
detect a difference in on our primary endpoint (i.e., stan-
dardized dyspnea rating) but the current sample size may
have been insufficient to detect possible differences in
some physiological variables. It is also important to
acknowledge that the small sample size makes it difficult to
generalize our findings to the COPD population as a whole.
Furthermore, the present study examined only the short-
term impact of FP500 on airway function beyond that
achieved by usual maintenance long-acting bronchodilators
of different classes. It is therefore unclear whether the
enhancement of bronchodilator effects is the result of
a unique interaction with LABA or occurs regardless of the
baseline bronchodilator choice.
In summary, this is the first study to examine the addi-
tional short term sensory and physiological effects of FP500
on airway function when added to regular maintenance
treatment with long-acting bronchodilators in stable COPD
patients. Following 2 weeks of FP500 therapy, we observed
no consistent improvement in dyspnea intensity ratings at
a standardized exercise time or ventilation but did show
clinically important improvements in secondary outcomes
which included spirometry, static lung volumes and
dynamic operating lung volumes during exercise compared
with PLA. Improvements in exercise endurance, though
statistically significant, were highly variable and the
mechanism of improvement is not fully understood.
Current guidelines suggest that ICS should be prescribed
for prevention of acute exacerbations in patients with
moderate to severe COPD. The current study provides new
evidence that the addition of ICS monotherapy to mainte-
nance bronchodilator therapy has the potential to provideadditional physiological benefits which may have positive
clinical implications.
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